Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.
Ann Allergy Asthma ImmunolJun 15, 2026 (epub)
Clinical ResearchAllergy & Immunology
Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized controlled trial evaluated the effects of remibrutinib on disease control, sleep, and quality of life in adults with chronic spontaneous urticaria (CSU) who were symptomatic despite antihistamine treatment. The study found significant improvements in urticaria activity and sleep interference within one week of treatment, with a change from baseline in Urticaria Activity Score of -11.8 for remibrutinib compared to -3.6 for placebo.
Key findings
- Remibrutinib led to a change from baseline Urticaria Activity Score of -11.8 compared to -3.6 for placebo.
- Sleep interference scores improved significantly with remibrutinib (-4.9) versus placebo (-1.9).
- Sustained improvements in quality of life measures were observed through week 52.
- Patients transitioning from placebo to remibrutinib also showed comparable improvements.
Why it matters
The findings highlight the potential of remibrutinib to rapidly enhance disease control and quality of life in patients with CSU, a condition that significantly impacts daily functioning and well-being.